Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
Tegoprubart
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Anelixis_Therapeutics
|
| gptkbp:intendedUse |
treatment of amyotrophic lateral sclerosis
|
| gptkbp:mechanismOfAction |
CD40 ligand antagonist
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:CD40L
|
| gptkbp:therapeuticArea |
neurodegenerative diseases
|
| gptkbp:bfsParent |
gptkb:Anelixis_Therapeutics
gptkb:Eledon_Pharmaceuticals |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
AT-1501
|